Evommune (EVMN) Retained Earnings (2024 - 2026)

Evommune (EVMN) posted quarterly Retained Earnings of -$242.8 million for Q1 2026, down 9.8% quarter-over-quarter from -$221.1 million in Q4 2025.

Evommune (EVMN) Retained Earnings (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Retained Earnings for 3 consecutive years, with -$242.8 million the latest figure, recorded in Q1 2026.

In Q1 2026, Retained Earnings changed N/A year-over-year to -$242.8 million; the TTM figure through Mar 2026 stood at -$242.8 million (changed N/A YoY), while the FY2025 annual figure was -$221.1 million, down 45.24% from the prior year.
Retained Earnings declined to -$242.8 million in Q1 2026 per EVMN's latest filing, from -$221.1 million in the prior quarter.
Across five years, Retained Earnings topped out at -$152.2 million in Q4 2024 and bottomed at -$242.8 million in Q1 2026.
Historically, Retained Earnings has averaged -$202.2 million across 3 years, with a median of -$206.9 million in 2025.
On a YoY basis, Retained Earnings climbed as much as 45.24% in 2025 and fell as far as 45.24% in 2025.
Evommune's Retained Earnings stood at -$152.2 million in 2024, then sank by 45.24% to -$221.1 million in 2025, then decreased by 9.8% to -$242.8 million in 2026.
Business Quant data shows EVMN's Retained Earnings at -$242.8 million in Q1 2026, -$221.1 million in Q4 2025, and -$192.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Retained Earnings (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	15.69 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	37.62 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-4.00 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.05 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-104.13 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	4.38 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-6.33 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.57 Bn
10	Evommune	531.53 Mn	330.73 Mn	-	-275.01 Mn

Download Data